New SHIKARI® S-ATB v2 ELISA kit for quantitative measurement of ADA to BEVACIZUMAB with confirmation and a new publication for usefulness of bevacizumab anti drug antibody measurement

Matriks Biotek® to introduce NEW SHIKARI® S-ATB v2 ELISA kit to measure anti-bevacizumab antibody levels and confirmation of the results with in the same kit. Along with measuring trough levels of bevacizumab with SHIKARI® Q-Beva v2 kit together can give definitive information about patient status when evaluated with different tests and clinical status of the patient.

When neutralizing antibodies occur after administration of Bevacizumab these antibodies block the effect of the drug and becomes ineffective during the course of treatment. 
Please refer to the publicatin below. We know from the published work for biological drugs that these antibodies can be transient and be overcomed by escalating the dose of the drug.  http://www.matriksbiotek.com/assets/files/articles/Choi.pdf 

New publication:












1553P H. Akbulut, M. Ocal, G. Sonugur, B. Akay, C. Babahan, S. Abdi Abgarmi,
A. Demirkazik, F. Icli.: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC).

Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
Annals of Oncology, Volume 27, 2016 Supplement 6, Abstract Book of the 41st ESMO Congress (ESMO 2016), 7–11 October 2016, Copenhagen, Denmark

According to published work four patients (10%) had measurable anti-bevacizumab levels. There was no objective response in patients with measurable antibevacizumab antibody levels.

For more information about Matriks Biotek SHIKARI ELISA kits for the measurement of drug and anti drug antibody levels please refer to www.matriksbiotek.com and ask a quote from info@matriksbiotek.com 

Matriks Biotek® SHIKARI® ELISA kits Distribution Partners

We are well distibuted all over the world. All ordered kits are delivered worldwide in 1 to 5 business days.
See the list of distributors in your area, 

http://matriksbiotek.com/distribution.html

or send us an email to info@matriksbiotek.com for direct orders

New article from University of Modena and Reggio Emilia, Modena, Italy, Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.PLoS ONE, 2016.

      Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.
     
     Drug and Anti-Drug Levels of Infliximab, Adalimumab and Etanercept are Measured by SHIKARI® ELISA Kits From Matriks Biotek®

The study suggests that a complex remodelling of the TNF-α/sTNFR system occurs in patients with psoriasis treated with anti-TNF-α drugs. Other studies are, however, needed to further characterize functional changes of monocytes in patients treated with different drugs, and that could devote their attention to other early, crucial aspects of inflammatory phenomena modulated by these drugs. Therefore, the correlations between plasma levels of TNF-α, its soluble receptor, the phenotype of monocytes and their ability to produce cytokines must be investigated also in other human diseases that benefit of he treatment with molecules that block TNF-α.

For fulltext article:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147951/pdf/pone.0167757.pdf 

List of All Articles

http://matriksbiotek.blogspot.com.tr/2016/12/publications-done-by-using-shikari.html

www.matriksbiotek.com